Biobetters: Advances in Biomanufacturing 2025-2033
The increasing availability of monoclonal antibodies further enriches the biobetters market. Moreover, the rise in chronic conditions, such as chronic kidney disease and chemotherapy-induced anemia, has contributed to this market expansion. A noteworthy aspect of biobetters is that patients are more likely to complete their treatment regimens owing to the improved dosing frequency associated with these medications.